



Biospace Lab announces its development plan on its optical *in vivo* imaging system

Photon IMAGER™ new features and add-ons to be launched in 2008

Paris (France), December 17th 2007 – Biospace lab, a pre-clinical research company in molecular imaging, announced today a major development plans on its Photon IMAGER™, optical system for bioluminescence and fluorescence preclinical imaging.

In addition to the In Actio™ module already commercialized for bioluminescence imaging on non-anesthetized animals, biospace lab is currently conducting internal R&D projects for developing new real-time and 3D bioluminescence / 3D fluorescence modules (patents pending technologies) that will lead to systems to be launched in second half of 2008.

"Our philosophy for developing our flagship product in optic is to bring new features and possible add-ons to the system so that users will be able to upgrade their system according to their needs and budget" said Serge Maitrejean, Chief Operating Officer, of biospace lab.

He added: *"We are also developing with the University of Pharmacy of Paris and the Ecole Supérieure de Chimie of Paris phosphorescent nanodots based on a principle of delayed fluorescence. These new optical markers might represent an alternative to the use of radioactive tracers in a number of applications, including at a longer term in diagnostics and clinical imaging. We are first going to spread this technology through collaborative agreement in small animal imaging with Photon IMAGER™ users for improving targeting and vectorization"*.

The Photon IMAGER™ is the latest addition to biospace lab' line of imaging instruments, which uses a very sensitive 3rd generation intensified Gallium Arsenide photocathode camera for *in vivo* bioluminescence and fluorescence. It is a unique instrument, allowing performing photon counting as opposed to light integration, which means a better signal to noise ratio, hence a better sensitivity, real time display and kinetic capabilities even with weak signals such as in bioluminescence.

"We are putting a lot of efforts in R&D on the Photon IMAGER™ system to satisfy the expressed needs of our clients and prospects" said Bruno Brisson, biospace lab' Chief Executive Officer. He added *"We are also engaged in implementing our other systems, which are also very competitive, especially in the quantitative autoradiography field. With an installed base of more than 200 systems over the world, these new developments will certainly help us in consolidating our position in the small animal imaging field"*.

Biospace was founded in 1989 by Nobel Prize winner Georges Charpak to provide fellow researchers in biology with innovative imaging tools based on his discoveries in high-energy physics and particle detection. Since then, biospace has pursued and created strong links with the medical, pharmaceutical and scientific communities to bring relevant and creative solutions to biomedical imaging needs.

Biospace lab (www.biospacelab.com) focuses on high-performance imaging equipment for pre-clinical research in drug discovery and biology. The company has developed in this field a comprehensive portfolio of *in vitro*, *in vivo* and now *in actio* multimodality small animal imaging solutions used by almost every major pharmaceutical company and many prestigious academic centers worldwide.

Biospace lab headquarters, development and production facilities are located in central Paris, France and the company has a subsidiary in Cambridge, MA USA.

Contacts: biospace lab, 10 rue Mercoeur - 75011 Paris, France
t + 33(0)1 55 25 60 60 f + 33(0)1 55 25 60 61 Email : info@biospacelab.com